QPS buys stake in Bioserve to expand Phase I business

- Last updated on GMT

QPS has bought a majority stake in India’s Bioserve Clinical Research to bolster its Phase I and bioanalytical business.

The deal, terms of which were not disclosed, will see the Indian contract research organisation's (CRO) 100-strong staff provide early-clinical trial and bioanalysis services to both local and multinational developers at its 92-bed research unit in Hyderabad under the QPS-Bioserve India.

QPS CEO Ben Chien said: “With access to Bioserve's additional resources, our customers will have the heightened benefits of a third more phase I beds, bringing our total to 400; greater bioanalytical capacity and access to another facility​.”

QPS, which offers a range of preclinical and clinical drug development services, is continuing with the growth through acquisition strategy which, last year​, saw it but Netherlands-based Xendo Drug Development (XDD) to expand its European business.

QPS joins Quintiles as the second western CRO to expand its Phase I trial offering in India this week.

Related news

Show more

Related products

VDS groß

Meet the challenges of complex injectables

Vetter Pharma International GmbH | 07-Nov-2017 | Technical / White Paper

In the time it takes from the exciting discovery phase to the rigorous demands of a commercial launch, unexpected scientific and technical challenges can...

Related suppliers